## Edgar Filing: PDL BIOPHARMA, INC. - Form 4

PDL BIOP	HARMA, INC.							
Form 4								
July 24, 200								
FORM		STATES SECI	RITIES	AND EXCHANGI	F COMMISSION		PPROVAL	
	UNITED			a, D.C. 20549		OMB Number:	3235-0287	
Check t			8	,		Expires:	January 31,	
if no lo subject		MENT OF CHA		BENEFICIAL O RITIES	WNERSHIP OF	Estimated average 200		
Section		burden hou	urs per					
Form 4 Form 5		count to Section	16(n) of t	he Securities Excha	hard A at of 1024	response	. 0.5	
obligati	ons Section 17(			lding Company Act	•	n		
may con See Inst	nunue.		•	t Company Act of				
1(b).	ruetion			1 0				
(Print or Type	Responses)							
1. Name and	Address of Reporting	Person * 2 Issi	ier Name <b>an</b>	d Ticker or Trading	5. Relationship of	Reporting Person(s) to		
Calcott Pet	Symbo		a field of flading	Issuer	1 0			
		PDL I	BIOPHAR	MA, INC. [PDLI]	(Check all applicable)			
(Last)	(First) (	Middle) 3. Date	of Earliest 7	Fransaction	(Check an applicable)			
			/Day/Year)		Director 10% Owner			
	BIOPHARMA,	07/20	/2006		X Officer (give below)	title Oth below)	ner (specify	
INC., 3480	01 CAMPUS DRI	VE			VP, Qua	lity & Compli	ance	
	4. If Ar	nendment, D	Date Original	6. Individual or Joint/Group Filing(Check				
		Filed(M	Ionth/Day/Yea	ar)	Applicable Line)	)		
FREMON	Г, СА 94555				_X_ Form filed by C Form filed by M			
TRENON	I, CA 94555				Person			
(City)	(State)	(Zip) Ta	ble I - Non-	Derivative Securities A	Acquired, Disposed of	, or Beneficia	lly Owned	
1.Title of	2. Transaction Date	2A. Deemed	3.	4. Securities		. Ownership	7. Nature of	
Security (Instr. 3)	(Month/Day/Year)	Execution Date, if	Transactio Code	onAcquired (A) or Disposed of (D)		Form: Direct D) or Indirect	Indirect Beneficial	
(IIIsu. 5)		any (Month/Day/Year)		(Instr. 3, 4 and 5)	•	I) of maneet	Ownership	
					U V	Instr. 4)	(Instr. 4)	
				(A)	Reported Transaction(s)			
			Code V	or Amount (D) Price	(Instr. 3 and 4)			
			coue ,		·			
Reminder: Re	port on a separate line	e for each class of se	curities bene	eficially owned directly	-			
					spond to the collec stained in this form		SEC 1474 (9-02)	
				required to resp	ond unless the form	n		
				displays a curre number.	ently valid OMB con	trol		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: PDL BIOPHARMA, INC. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	,	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 17.13	07/20/2006		A		21,000		<u>(1)</u>	07/20/2013	Common Stock	21,000

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
1 0	Director	10% Owner	Officer	Other				
Calcott Peter H C/O PDL BIOPHARMA, INC. 34801 CAMPUS DRIVE FREMONT, CA 94555	VP, Quality & Compliance							
Signatures								
/s/ George Jue by George Jue, Att Calcott	er H.	07/24/2006						
<u>**</u> Signature of Repo	orting Perso	n		Date				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option vests with respect to 1/48 of the shares per month over four years after the date of grant. Only vested options are exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.